USPTO Examiner YOUNG MICAH PAUL - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18917080PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPIONOctober 2024April 2025Allow611YesNo
18811352PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODELAugust 2024February 2025Allow610NoNo
18640730STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIBApril 2024June 2025Allow1430NoNo
18637037HYDROPHOBIC TOPICAL COMPOSITIONS AND METHODS FOR PRODUCING SAMEApril 2024January 2025Allow910NoNo
18618520COMPOSITIONS COMPRISING ATICAPRANTMarch 2024September 2024Allow510NoNo
18612370CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIAMarch 2024June 2025Abandon1410NoNo
18612430Formulations Of ApremilastMarch 2024March 2025Allow1210NoNo
18607237DEVICE AND METHOD FOR TREATING CANCERMarch 2024April 2025Allow1321YesNo
18595026USE OF SACCHARIDES FOR CRYOPROTECTION AND RELATED TECHNOLOGYMarch 2024June 2025Abandon1510NoNo
18590452BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSFebruary 2024October 2024Allow820NoNo
18582459APPLICATOR AND SYSTEM FOR ADMINISTERING AND DISPENSING FLOWABLE PHARMACEUTICAL PREPARATIONSFebruary 2024June 2025Allow1610NoNo
18435245PHARMACEUTICAL FORMULATIONSFebruary 2024April 2025Abandon1410NoNo
18415196BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSJanuary 2024December 2024Allow1120NoNo
18543759NOVEL GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORMDecember 2023May 2025Abandon1610NoNo
183836484-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow501NoNo
18483007TABLET FOR ORAL SUSPENSIONOctober 2023March 2025Allow1710NoNo
18376038SKIN SOLUTION WITH SOLUBILIZED BAKUCHIOLOctober 2023June 2025Allow2010NoNo
18478524ORAL POUCH PRODUCTSeptember 2023December 2024Allow1530NoNo
18243735STABLE SOLID FINGOLIMOD DOSAGE FORMSSeptember 2023March 2025Abandon1810NoNo
18456300PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODELAugust 2023August 2024Allow1221YesNo
18451030Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK InhibitorAugust 2023September 2024Allow1310NoNo
18353323BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSJuly 2023November 2023Allow410NoNo
18346115COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMSJune 2023January 2025Allow1820NoNo
18333785BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSJune 2023December 2023Allow630NoNo
18208775NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENTJune 2023February 2025Abandon2010NoNo
18321173DRUG DELIVERY SYSTEMS AND METHODS FOR MAKING AND USING THE SAMEMay 2023July 2024Allow1410YesNo
18196718Formulations Of ApremilastMay 2023December 2023Allow710NoNo
18315618Implantable Device for Sustained Release of a Macromolecular Drug CompoundMay 2023May 2024Allow1210NoNo
18300739NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATIONApril 2023July 2024Allow1510NoNo
18296954LIMIT SIZE LIPID NANOPARTICLES AND RELATED METHODSApril 2023October 2024Allow1920NoNo
18191910TABLET FOR ORAL SUSPENSIONMarch 2023February 2024Abandon1010NoNo
18184443Methylphenidate Extended Release Chewable TabletMarch 2023January 2025Abandon2220NoNo
18118919Concentrated Nutritional or Supplemental Compound for Intestinal, Gut-Brain Axis and Neurobiological Homeostasis through Calibrated Absorption Including Neurotransmitter or Any Equilibrating Compound Release to Treat or Mitigate Disease and Co-morbidities, Particularly Obesity and Malnourishment.March 2023September 2023Allow710NoNo
18179093COMPOSITIONS COMPRISING ATICAPRANTMarch 2023May 2024Abandon1520NoNo
18177348GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORMMarch 2023October 2023Allow720YesNo
18007247NOVEL GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORMJanuary 2023May 2025Abandon2710NoNo
18158128HYDROPHOBIC TOPICAL COMPOSITIONS AND METHODS FOR PRODUCING SAMEJanuary 2023October 2023Allow810NoNo
18157393BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSJanuary 2023May 2023Allow410YesNo
18154566MICRONEEDLE PATCH FOR DELIVERING AN ACTIVE INGREDIENT TO SKINJanuary 2023June 2024Abandon1710NoNo
18092928USE OF SACCHARIDES FOR CRYOPROTECTION AND RELATED TECHNOLOGYJanuary 2023June 2024Abandon1710NoNo
18091481STABLE SOLID FINGOLIMOD DOSAGE FORMSDecember 2022February 2024Abandon1310NoNo
18074996Cerium Oxide Nanoparticle Compositions and MethodsDecember 2022June 2025Allow3031NoNo
18074699TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONSDecember 2022September 2024Allow2120NoNo
18049136COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLESOctober 2022June 2024Abandon2020NoNo
17937525METHODS AND PRODUCTS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDERSOctober 2022September 2023Allow1121NoNo
17958678TREATMENT OF PAIN BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONSOctober 2022September 2023Allow1230NoNo
17952691Concentrated Nutritional or Supplemental Compound for Intestinal, Gut-Brain Axis and Neurobiological Homeostasis through Calibrated Absorption Including Neurotransmitter or Any Equilibrating Compound Release to Treat or Mitigate Disease and Co-morbidities, Particularly Obesity and Malnourishment.September 2022August 2023Allow1110YesNo
17899769Formulations Of ApremilastAugust 2022April 2023Allow810NoNo
17864632EXTENDED RELEASE COMPOSITIONS COMPRISING TRIHEXYPHENIDYLJuly 2022February 2023Allow710NoNo
17862854PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASEJuly 2022January 2023Abandon610NoNo
17790429TREATMENT OF PAIN BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONSJune 2022March 2025Abandon3210NoNo
17848685COMPOSITIONS FOR DELIVERY OF REBOXETINEJune 2022December 2023Allow1710NoNo
17849426DRUG-COATED MEDICAL DEVICESJune 2022September 2024Allow2730YesNo
17840382TABLET FOR ORAL SUSPENSIONJune 2022December 2022Allow610YesNo
17750648STABLE LOW DIGESTIVE ENZYME CONTENT FORMULATIONMay 2022March 2025Allow3410NoNo
17747276SOLID PREPARATION CONTAINING TAFAMIDIS AND METHOD FOR PRODUCING THE SAMEMay 2022September 2024Abandon2810NoNo
17698787METHOD FOR FABRICATION OF ADDITIVELY MANUFACTURED, SELF-GELLING STRUCTURES AND THEIR USEMarch 2022December 2023Allow2131YesNo
17696997NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATIONMarch 2022March 2023Allow1220YesNo
17693830FORMULATIONS OF PIMAVANSERINMarch 2022May 2022Allow210NoNo
17641020THERAPEUTIC FORMULATIONS AND USES THEREOFMarch 2022May 2025Allow3810NoNo
17673331METHODS OF TREATING ALLERGIC CONJUNCTIVITISFebruary 2022September 2024Allow3150YesYes
17576242SOLID TABLET DOSAGE FORM OF RIDINILAZOLEJanuary 2022January 2025Allow3610NoNo
17573333BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULESJanuary 2022September 2023Allow2010NoNo
17624329SUSTAINED RELEASE COMPOSITIONS OF ENDOXIFENDecember 2021April 2024Allow2730YesNo
17521974Labeled Probe and Methods of UseNovember 2021September 2024Allow3511NoNo
17602934DISPERSIBLE TABLET COMPOSITIONOctober 2021May 2025Abandon4310NoNo
17496234PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASEOctober 2021April 2022Allow610NoNo
17482672EXTENDED RELEASE COMPOSITIONS COMPRISING TRIHEXYPHENIDYLSeptember 2021April 2022Allow720YesNo
17437353ULTRAFINE IRON OXIDE NANOPARTICLE-BASED MAGNETIC RESONANCE IMAGING T1 CONTRAST AGENTSeptember 2021April 2025Abandon4301NoNo
17464745IN SITU GELLING COMPOSITION AS A PH-SELECTIVE AND MUCOADHESIVE SUSTAINED RELEASE DRUG DELIVERY SYSTEMSeptember 2021March 2022Allow610YesNo
17406137BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULESAugust 2021November 2023Allow2720NoNo
17444402TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTSAugust 2021May 2024Allow3320NoYes
17394059Extended Release Methazolamide FormulationAugust 2021July 2022Allow1110NoNo
17310125GERM-REPELLENT BOOK AND FOOD PAPER PACKAGING, AND METHOD OF MANUFACTUREJuly 2021June 2024Allow3501NoNo
17373906METHOD FOR MANUFACTURING MARKER WITH AERATED HYDROGELJuly 2021November 2024Allow4020YesNo
17370778Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK InhibitorJuly 2021May 2023Allow2210NoNo
17360727COMPLEXES OF HYDROTALCITES AND FIBERSJune 2021December 2023Abandon2920NoNo
17309557COATABLE CORE FOR A MODIFIED RELEASE DRUG FORMULATIONJune 2021March 2025Allow4630NoNo
17309554METHOD OF PRODUCING A DELAYED RELEASE DRUG FORMULATIONJune 2021March 2025Allow4640YesNo
17298624ANTIBODY-DRUG CONJUGATES AND USE OF ANTIBODIES FOR DRUG DELIVERYMay 2021June 2025Abandon4820NoNo
17326826ORAL ADMINISTRATION OF 5-FU IN A GELLING NANOSUSPENSION FOR TARGETED DELIVERY TO TREAT COLORECTAL CANCERSMay 2021February 2022Allow911YesNo
17321729NOVEL PREVENTIVE AND THERAPEUTIC TREATMENT FOR COVID 19 AND ANY OTHER DISEASE CAUSED BY SARS COV 2May 2021July 2024Allow3850NoYes
17320155THERAPEUTIC SOLID DOSAGE FORMSMay 2021May 2024Allow3620NoNo
17317630DUAL RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMBINATION OF A BETA-3 ADRENORECEPTOR AGONIST AND A MUSCARINIC RECEPTOR ANTAGONISTMay 2021December 2023Abandon3110NoNo
17315133METHYLPHENIDATE COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDERMay 2021January 2023Abandon2120NoYes
17245842COMPOSITIONS AND METHODS FOR MEASURING AND EXPANDING BLOOD VOLUMEApril 2021July 2023Abandon2610NoNo
17290042LAXATIVE TABLETApril 2021June 2024Allow3710YesNo
17226848PHARMACEUTICAL FORMULATIONSApril 2021November 2023Allow3110NoNo
17222239PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASEApril 2021July 2021Allow410NoNo
17280986TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACEMarch 2021February 2025Allow4610NoNo
17216195OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE RELEASING PROSTAMIDEMarch 2021August 2024Allow4140NoNo
17213744Methylphenidate Extended Release Chewable TabletMarch 2021July 2021Allow420NoNo
17209604BONE VOID FILLER PREPARATION SYSTEMMarch 2021November 2023Allow3111YesNo
17201142Co-Processed Lubricant:MCG for TabletsMarch 2021November 2023Allow3210NoNo
17275915FLUORINATION METHODMarch 2021December 2024Abandon4511NoNo
17272378WIPEMarch 2021May 2024Abandon3920NoNo
17184506NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENTFebruary 2021September 2023Abandon3110NoNo
17270573NOVEL METHODSFebruary 2021November 2023Allow3320NoNo
17177569STABLE SOLID FINGOLIMOD DOSAGE FORMSFebruary 2021June 2023Abandon2710NoNo
17175764IN SITU GELLING COMPOSITION AS A PH-SELECTIVE AND MUCOADHESIVE SUSTAINED RELEASE DRUG DELIVERY SYSTEMFebruary 2021January 2022Allow1121YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YOUNG, MICAH PAUL.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
54
Examiner Affirmed
35
(64.8%)
Examiner Reversed
19
(35.2%)
Reversal Percentile
55.7%
Higher than average

What This Means

With a 35.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
212
Allowed After Appeal Filing
50
(23.6%)
Not Allowed After Appeal Filing
162
(76.4%)
Filing Benefit Percentile
28.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner YOUNG, MICAH PAUL - Prosecution Strategy Guide

Executive Summary

Examiner YOUNG, MICAH PAUL works in Art Unit 1618 and has examined 1,051 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner YOUNG, MICAH PAUL's allowance rate of 52.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by YOUNG, MICAH PAUL receive 2.84 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by YOUNG, MICAH PAUL is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +29.2% benefit to allowance rate for applications examined by YOUNG, MICAH PAUL. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 32.8% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 62.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 63.3% of appeals filed. This is in the 37% percentile among all examiners. Of these withdrawals, 53.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.7% are granted (fully or in part). This grant rate is in the 41% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.